> Detailanzeige

Messina, Monica; Piciocchi, Alfonso; Ottone, Tiziana; Paolini, Stefania; Papayannidis, Cristina; Lessi, Federica; Fracchiolla, Nicola Stefano; Forghieri, Fabio; Candoni, Anna; Mengarelli, Andrea; Martelli, Maria Paola; Venditti, Adriano; Carella, Angelo Michele; Albano, Francesco; Mancini, Valentina; Massimo, Bernardi; Arena, Valentina; Sargentini, Valeria; Sciumè, Mariarita; Pastore, Domenico; Todisco, Elisabetta; Roti, Giovanni; Siragusa, Sergio; Ladetto, Marco; [...]

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
  • Beteiligte: Messina, Monica; Piciocchi, Alfonso; Ottone, Tiziana; Paolini, Stefania; Papayannidis, Cristina; Lessi, Federica; Fracchiolla, Nicola Stefano; Forghieri, Fabio; Candoni, Anna; Mengarelli, Andrea; Martelli, Maria Paola; Venditti, Adriano; Carella, Angelo Michele; Albano, Francesco; Mancini, Valentina; Massimo, Bernardi; Arena, Valentina; Sargentini, Valeria; Sciumè, Mariarita; Pastore, Domenico; Todisco, Elisabetta; Roti, Giovanni; Siragusa, Sergio; Ladetto, Marco; [...]
  • Erschienen: MDPI AG, 2022
  • Erschienen in: Cancers
  • Sprache: Englisch
  • DOI: 10.3390/cancers14123012
  • ISSN: 2072-6694
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>IDH1/2 mutations are common in acute myeloid leukemia (AML) and represent a therapeutic target. The GIMEMA AML1516 observational protocol was designed to study the prevalence of IDH1/2 mutations and associations with clinico-biological parameters in a cohort of Italian AML patients. We analyzed a cohort of 284 AML consecutive patients at diagnosis, 139 females and 145 males, of a median age of 65 years (range: 19–86). Of these, 38 (14%) harbored IDH1 and 51 (18%) IDH2 mutations. IDH1/2 mutations were significantly associated with WHO PS &gt;2 (p &lt; 0.001) and non-complex karyotype (p = 0.021) when compared to IDH1/2-WT. Furthermore, patients with IDH1 mutations were more frequently NPM1-mutated (p = 0.007) and had a higher platelet count (p = 0.036). At relapse, IDH1/2 mutations were detected in 6 (25%) patients. As per the outcome, 60.5% of IDH1/2-mutated patients achieved complete remission; overall survival and event-free survival at 2 years were 44.5% and 36.1%, respectively: these rates were similar to IDH1/2-WT. In IDH1/2-mutated patients, high WBC proved to be an independent prognostic factor for survival. In conclusion, the GIMEMA AML1516 confirms that IDH1/2 mutations are frequently detected at diagnosis and underlines the importance of recognizing IDH1/2-mutated cases up-front to offer the most appropriate therapeutic strategy, given the availability of IDH1/2 inhibitors.</jats:p>
  • Zugangsstatus: Freier Zugang